British Association of Dermatologists Biologic Interventions Register (BADBIR) (United Kingdom) **

Database Contact Data

BADBIR
The University of Manchester
First Floor Bright Building
Manchester Science Park
Manchester M15 6GZ
UNITED KINGDOM
Main Office Phone: +44 0161 306 1896
Email: badbir@manchester.ac.uk

Alternate Contact

N/A

References of Studies Using/Describing Database

1. Williams K, Lada G, Reynolds NJ, Mcelhone K, Evans I, Warren RB, Walton S, Hughes O, Bewley A, Mason K, Kleyn CE. Risk of suicide and suicidality in patients with moderate to severe psoriasis: results from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Clin Exp Dermatol. 2025 Mar 26;50(4):804-811.

2. Phan DB, Jourdain H, Descalzo-Gallego MA, González-Quesada A, Zureik M, Rivera-Díaz R, Sahuquillo-Torralba A, Lunt M, Garcia-Doval I, Sbidian E, Warren RB, Yiu ZZN. Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study. Br J Dermatol. 2025 Mar 18;192(4):641-652.

3. Alabas OA, Mason KJ, Yiu ZZ, Warren RB, Dand N, Barker JN, Smith CH, Griffiths CE. The association of age at psoriasis onset and HLA-C* 06: 02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology. 2024 May;190(5):689-700.

4. Mason KJ, Alabas OA, Dand N, Warren RB, Reynolds NJ, Barker JN, Yiu ZZ, Smith CH, Griffiths CE. Characteristics of ‘super responders’ and ‘super nonresponders’ to first biologic monotherapy for psoriasis: a nested case–control study. British Journal of Dermatology. 2024 Mar;190(3):441-4.

5. Al-Janabi A, Alabas OA, Yiu ZZ, Foulkes AC, Eyre S, Khan AR, Reynolds NJ, Smith CH, Griffiths CE, Warren RB, Laws P. Risk of paradoxical eczema in patients receiving biologics for psoriasis. JAMA dermatology. 2024 Jan 1;160(1):71-9.

6. Al-Janabi A, Martin P, Khan AR, Foulkes AC, Smith CH, Griffiths CE, Morris AP, Eyre S, Warren RB, Ahmed S, Alabas O. Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics. Journal of Allergy and Clinical Immunology. 2023 Nov 1;152(5):1237-46.

7. Alabas OA, Mason KJ, Yiu ZZ, Warren RB, Lunt M, Smith CH, Griffiths CE. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology. 2023 Sep;189(3):271-8.

8. Al-Janabi A, Eyre S, Foulkes AC, Khan AR, Dand N, Burova E, DeSilva B, Makrygeorgou A, Davies E, Smith CH, Griffiths CE. Atopic polygenic risk score is associated with paradoxical eczema developing in patients with psoriasis treated with biologics. Journal of Investigative Dermatology. 2023 Aug 1;143(8):1470-8.

9. Phan DB, Elyoussfi S, Stevenson M, Lunt M, Warren RB, Yiu ZZ. Biosimilars for the treatment of psoriasis: a systematic review of clinical trials and observational studies. JAMA dermatology. 2023 Jul 1;159(7):763-71.

10. Phan DB, Bewley AP, Smith CH, Mackenzie T, Griffiths CE, Lunt M, Warren RB, Yiu ZZ. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). British Journal of Dermatology. 2023 Jul;189(1):62-70.

Mar 22, 2023: Why are some databases not currently profiled on B.R.I.D.G.E. TO DATA®?

The main goal of B.R.I.D.G.E. is to profile databases from around the world with the most current information. Therefore, B.R.I.D.G.E. profiles databases as new ones are created. We usually work with each database manager to ensure their database profile is complete and accurate. Although we try to include as many profiles on our web site as possible, we unfortunately cannot profile every database.

Mar 14, 2023: Read about our 8th healthcare database profile from Estonia

Established in January 2015, the Estonian Cancer Screening Register records data on the 3 available population-based cancer screenings in Estonia: breast, cervical and colorectal cancer. While the breast cancer screening started in 2003, and the cervical cancer screening in 2006, the data have been added to ECSR only since 2015, while colorectal cancer screening data in Estonia were added to the register in 2016.

National Congenital Anomaly and Rare Disease Registration Service (NCARDRS) (United Kingdom)

Database Contact Data

For requests for data which sit under the National Congenital Anomaly and Rare Diseases Registration Service (NCARDRS) suite of products, please email ndrsenquiries@nhs.net.

To discuss any aspect of DARS or an existing application call the team on +44 (0)300 303 5678 or email enquiries@nhsdigital.nhs.uk.

Alternate Contact

1. Danielle Martin
National Senior Data Analyst 
National Congenital Anomaly and Rare Disease Registration Service (NCARDRS) 
Public Health England
Wellington House
133-155 Waterloo Road
London, England SE1 8UG
UNITED KINGDOM
Email: danielle.martin@phe.gov.uk  
Phone: +44 (0)191 242 6003
Mobile: +44 (0) 7554111236

2. If you cannot reach the database manager, you may contact the organization by completing the contact form at: https://digital.nhs.uk/ndrs/ndrs-contact-page

References of Studies Using/Describing Database

1. Cave DGW, Wands ZE, Cromie K, Hough A, Johnson K, Mon-Williams M, Bentham JR, Feltbower RG, Glaser AW. Educational attainment of children with congenital heart disease in the United Kingdom. Eur Heart J Qual Care Clin Outcomes. 2024 Aug 8;10(5):456-466. 

2. Broughan JM, Martin D, Higgins T, Swan G, Cullum A, Kurinczuk JJ, Draper ES, Luyt K, Wellesley DG, Stevens S, Tedstone A, Rankin J. Prevalence of neural tube defects in England prior to the mandatory fortification of non-wholemeal wheat flour with folic acid: a population-based cohort study. Arch Dis Child. 2024 Jan 22;109(2):106-112.

3. Broughan JM, Wreyford B, Martin D, Melis G, Randall K, Obaro E, Broggio J, Aldridge N, Stoianova S, Johnson C, Gibbard D, Stevens S, Fleming KM. Cohort profile: the National Congenital Anomaly Registration Dataset in England. BMJ Open. 2024 Jan 12;14(1):e077743.

4. Odingo M, Rutter M, Bowley J, Peach EJ, Lanyon PC, Grainge MJ, Stillwell P, McPhail S, Bythell M, Aston J, Stevens S, McCormack R, Brogan P, Pearce FA. The incidence of Kawasaki disease using hospital admissions data for England 2006-2021. Rheumatology (Oxford). 2023 Sep 1;62(9):3117-3125.

5. Moss C, Roked F, Davis PJ, Khan M, Tyler C, Ibbs S, Ewer AK. Birth incidence and outcome of harlequin ichthyosis and collodion membrane in the UK and Ireland: a national 2-year prospective surveillance study. British Journal of Dermatology. 2023 Jan;188(1):139-40.

6. Aldridge N, Pandya P, Rankin J, Miller N, Broughan J, Permalloo N, McHugh A, Stevens S. Detection rates of a national fetal anomaly screening programme: A national cohort study. BJOG: An International Journal of Obstetrics & Gynaecology. 2023 Jan;130(1):51-8.

7. Melis G, Martin D, Obaro E, Tempest E, Broughan J, Miller N. P25 The national congenital anomaly and rare disease registration service (NCARDRS): data profile, its application and development towards administrative data linkage in England. 2023; A65-A66.

8. Aslam AA, Baksh RA, Pape SE, Strydom A, Gulliford MC, Chan LF, Go-DS21 Consortium, Herault Yann Strydom Andre Chan Li Potier Marie-Claude Beckers Johannes Liò Pietro Dierssen Mara. Diabetes and obesity in Down Syndrome across the lifespan: a retrospective cohort study using UK electronic health records. Diabetes care. 2022 Dec;45(12):2892-9.

9. West J, Stilwell P, Liu H, Ban L, Bythell M, Card T, Lanyon P, Nanduri V, Rankin J, Bishton M, Crooks C. Factors Influencing 1-Year Survival in Haemphagocytic Lymphohistiocytosis: A National Cohort Study in England. Blood. 2022 Nov 15;140(Supplement 1):5469-70.

10. Bishton M, Crooks C, Liu H, Ban L, Bythell M, Card T, Lanyon P, Nanduri V, Rankin J, Stilwell P, West J. Haemphagocytic Lymphohistiocytosis in an English Nationwide Cohort Confirms Increasing Incidence and Variation in Trigger Factors. Blood. 2022 Nov 15;140(Supplement 1):2599-600.

Estonian Cancer Screening Register (Estonia)

Database Contact Data

The Estonian Cancer Screening Register
National Institute for Health Development
Paldiski mnt 80
Tallinn
ESTONIA
Phone +372 5388 9686
Email: soeluuring@tai.ee

Alternate Contact

N/A

References of Studies Using/Describing Database

1. Orumaa M, Innos K, Suurna M, Veerus P. Cervical cancer screening history among women diagnosed with cervical cancer in Estonia 2017-18. Eur J Public Health. 2023 Feb 3;33(1):64-68.

2. Reima H, Soplepmann J, Elme A, Lõhmus M, Tiigi R, Uksov D, Innos K. Changes in the quality of care of colorectal cancer in Estonia: a population-based high-resolution study. BMJ Open. 2020 Oct 8;10(10):e035556. doi: 10.1136/bmjopen-2019-035556.

3. Analysis of selected quality indicators in the Estonian cervical cancer screening program in 2016. Anion, E; Veerus, P. Master thesis. Defended 2018.

4. Vaccarella S, Franceschi S, Zaridze D, Poljak M, Veerus P, Plummer M, Bray F. Preventable fractions of cervical cancer via effective screening in six Baltic, central, and eastern European countries 2017-40: a population-based study. Lancet Oncol. 2016 Oct;17(10):1445-1452.

5. Innos K, Valvere V, Padrik P, Eelma E, Kütner R, Lehtsaar J, Tekkel M. Mammography use and mode of detection among breast cancer patients in Estonia. Women Health. 2016;56(2):129-40.

6. Veerus P, Arbyn M, Amati C, Paolo B; EUROCHIP Working Group. Impact of implementing a nationwide cervical cancer screening program on female population coverage by Pap-tests in Estonia. Tumori. 2010 Jul-Aug;96(4):524-8.

Subscribe to